Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead
Department of Medical Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2006, 13(1), 8-13; https://doi.org/10.3747/co.v13i1.91
Submission received: 1 November 2005
/
Revised: 2 December 2005
/
Accepted: 3 January 2006
/
Published: 1 February 2006
Abstract
The major breast cancer story of 2005 was trastuzumab, a monoclonal antibody directed against the Her-2 oncoprotein, and how it greatly improves outcomes for women with HER2-positive early-stage breast cancer. With early results showing that use of the drug can prevent roughly one half of relapses, adjuvant trastuzumab has been approved, funded, and accepted as the standard of care in many Canadian jurisdictions. In the present brief report, we summarize the four major adjuvant trials, outline some key controversies, and suggest steps to provide more-effective and better-tolerated adjuvant systemic therapy for the relevant patient subgroup.
Share and Cite
MDPI and ACS Style
Joy, A.A.; Mackey, J.R. Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead. Curr. Oncol. 2006, 13, 8-13. https://doi.org/10.3747/co.v13i1.91
AMA Style
Joy AA, Mackey JR. Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead. Current Oncology. 2006; 13(1):8-13. https://doi.org/10.3747/co.v13i1.91
Chicago/Turabian StyleJoy, A.A., and J.R. Mackey. 2006. "Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead" Current Oncology 13, no. 1: 8-13. https://doi.org/10.3747/co.v13i1.91
